A Phase 1/2 interventional study of delandistrogene moxeparvovec in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 3 Months to 7 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 11th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 3 Months to 7 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 5 started in 2018.
This study's enrollment of 4 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was an open-label single-dose gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec intravenous (IV) administration in boys with DMD. This study was originally designed to consist of 12 patients across 2 Cohorts. Cohort A would have included participants ages 3 months to 3 years, and Cohort B included participants ages 4 to 7 years old. No participants were enrolled in Cohort A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion or exclusion criteria could apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
Genetic: delandistrogene moxeparvovec
Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.
Genetic: delandistrogene moxeparvovec
Single IV infusion of delandistrogene moxeparvovec.
Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of a study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Up to 5 years
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin protein levels in these muscle biopsy samples was determined by Western blot. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
Time frame: Baseline, Day 90
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF fiber intensity indicates increased delandistrogene moxeparvovec dystrophin expression.
Time frame: Baseline, Day 90
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF)
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates increased delandistrogene moxeparvovec dystrophin expression.
Time frame: Baseline, Day 90
Change From Baseline at Year 5 in the 100 Meter Timed Test
This assessment measures the time needed to move 100 meters and served as the primary motor outcome measure for this study. A decrease in the time needed to move 100 meters indicates increased motor function.
Time frame: Baseline, Year 5
| Milestone | Delandistrogene Moxeparvovec |
|---|---|
| Started | 4 |
| Received at least 1 dose of study drug | 4 |
| Completed | 4 |
| Not completed | 0 |
An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of a study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Delandistrogene Moxeparvovec |
|---|---|
| Number of Participants With Adverse Events (AEs) | 4 |
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin protein levels in these muscle biopsy samples was determined by Western blot. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.
| percent control | Delandistrogene Moxeparvovec |
|---|---|
| Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot | 70.52 ± 76.10 |
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF fiber intensity indicates increased delandistrogene moxeparvovec dystrophin expression.
| percent fluorescent expression | Delandistrogene Moxeparvovec |
|---|---|
| Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity | 93.59 ± 43.86 |
Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates increased delandistrogene moxeparvovec dystrophin expression.
| percent dystrophin positive fibers | Delandistrogene Moxeparvovec |
|---|---|
| Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF) | 81.18 ± 10.19 |
This assessment measures the time needed to move 100 meters and served as the primary motor outcome measure for this study. A decrease in the time needed to move 100 meters indicates increased motor function.
| second | Delandistrogene Moxeparvovec |
|---|---|
| Change From Baseline at Year 5 in the 100 Meter Timed Test | -4.02 ± 4.64 |
Collected over Up to 5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delandistrogene Moxeparvovec | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Delandistrogene Moxeparvovec |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/4 |
| VomitingGastrointestinal disorders | 4/4 |
| Hepatic enzyme increasedInvestigations | 3/4 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/4 |
| FatigueGeneral disorders | 2/4 |
| COVID-19Infections and infestations | 2/4 |
| Procedural painInjury, poisoning and procedural complications | 2/4 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/4 |
| Abdominal discomfortGastrointestinal disorders | 1/4 |
Full Analysis Set: all participants who received study treatment.
| Age, Continuous(years) | Delandistrogene Moxeparvovec |
|---|---|
| Mean | 5.14 ± 0.91 |
| Age, Customized(Participants) | Delandistrogene Moxeparvovec |
|---|---|
| In utero | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 4 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65-84 years | 0 |
| 85 years and over | 0 |
| Sex: Female, Male(Participants) | Delandistrogene Moxeparvovec |
|---|---|
| Female | 0 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Delandistrogene Moxeparvovec |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Delandistrogene Moxeparvovec |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 3 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
Ran from Jan 2018 to primary completion in Apr 2023, 63 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 63 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →